These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24971173)

  • 1. Comparison of Postprandial Responses to a High-Fat Meal in Hypertriglyceridemic Men and Women before and after Treatment with Fenofibrate in the Genetics and Lipid Lowering Drugs and Diet Network (GOLDN) Study.
    Glasser SP; Wojczynski MK; Oberman AI; Kabagambe EK; Tsai MY; Ordovas JM; Straka RJ; Arnett DK
    SRX Pharmacol; 2010; 2010():485146. PubMed ID: 24971173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN): an interventional study.
    Wojczynski MK; Glasser SP; Oberman A; Kabagambe EK; Hopkins PN; Tsai MY; Straka RJ; Ordovas JM; Arnett DK
    Lipids Health Dis; 2011 Oct; 10():181. PubMed ID: 22008512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network.
    Tsai MY; Ordovas JM; Li N; Straka RJ; Hanson NQ; Arends VL; Arnett D
    Mol Genet Metab; 2010 Jun; 100(2):118-22. PubMed ID: 20346718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.
    Irvin MR; Kabagambe EK; Tiwari HK; Parnell LD; Straka RJ; Tsai M; Ordovas JM; Arnett DK
    Circ Cardiovasc Genet; 2010 Oct; 3(5):462-7. PubMed ID: 20729559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An exome-wide sequencing study of lipid response to high-fat meal and fenofibrate in Caucasians from the GOLDN cohort.
    Geng X; Irvin MR; Hidalgo B; Aslibekyan S; Srinivasasainagendra V; An P; Frazier-Wood AC; Tiwari HK; Dave T; Ryan K; Ordovas JM; Straka RJ; Feitosa MF; Hopkins PN; Borecki I; Province MA; Mitchell BD; Arnett DK; Zhi D
    J Lipid Res; 2018 Apr; 59(4):722-729. PubMed ID: 29463568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study.
    Ikewaki K; Tohyama J; Nakata Y; Wakikawa T; Kido T; Mochizuki S
    J Atheroscler Thromb; 2004; 11(5):278-85. PubMed ID: 15557710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide association study of triglyceride response to a high-fat meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network (GOLDN).
    Wojczynski MK; Parnell LD; Pollin TI; Lai CQ; Feitosa MF; O'Connell JR; Frazier-Wood AC; Gibson Q; Aslibekyan S; Ryan KA; Province MA; Tiwari HK; Ordovas JM; Shuldiner AR; Arnett DK; Borecki IB
    Metabolism; 2015 Oct; 64(10):1359-71. PubMed ID: 26256467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
    Rosenson RS; Wolff DA; Huskin AL; Helenowski IB; Rademaker AW
    Diabetes Care; 2007 Aug; 30(8):1945-51. PubMed ID: 17483155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy.
    Rosenson RS; Helenowski IB; Tangney CC
    Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):439-47. PubMed ID: 20922563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
    Lai CQ; Arnett DK; Corella D; Straka RJ; Tsai MY; Peacock JM; Adiconis X; Parnell LD; Hixson JE; Province MA; Ordovas JM
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1417-25. PubMed ID: 17431185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome.
    Rosenson RS; Huskin AL; Wolff DA; Helenowski IB; Rademaker AW
    Atherosclerosis; 2008 Jun; 198(2):381-8. PubMed ID: 18242616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size.
    Suter PM; Marmier G; Veya-Linder C; Hänseler E; Lentz J; Vetter W; Otvos J
    Atherosclerosis; 2005 May; 180(1):127-35. PubMed ID: 15823285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of postprandial variation in triglyceridemia on low-density lipoprotein particle size.
    Blackburn P; Côté M; Lamarche B; Couillard C; Pascot A; Tremblay A; Bergeron J; Lemieux I; Després JP
    Metabolism; 2003 Nov; 52(11):1379-86. PubMed ID: 14624394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postprandial lipoprotein responses in hypertriglyceridemic subjects with and without cardiovascular disease.
    Hughes TA; Elam MB; Applegate WB; Bond MG; Hughes SM; Wang X; Tolley EA; Bittle JB; Stentz FB; Kang ES
    Metabolism; 1995 Aug; 44(8):1082-98. PubMed ID: 7637651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.
    Genest J; Nguyen NH; Theroux P; Davignon J; Cohn JS
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):164-72. PubMed ID: 10630748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a cardioselective beta-blocker on postprandial triglyceride-rich lipoproteins, low density lipoprotein particle size and glucose-insulin homeostasis in middle-aged men with modestly increased cardiovascular risk.
    Boquist S; Ruotolo G; Hellénius ML; Danell-Toverud K; Karpe F; Hamsten A
    Atherosclerosis; 1998 Apr; 137(2):391-400. PubMed ID: 9622282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.
    Chan SY; Mancini GB; Ignaszewski A; Frohlich J
    BMC Clin Pharmacol; 2008 Oct; 8():10. PubMed ID: 18957124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.